Hepagard solution for injection, 100 ml
Storage
1 ml of the drug contains: L-ornithine – 15 mg, L-citrulline – 10 mg, L-arginine – 40 mg, as well as auxiliary substances: betaine, sorbitol, lidocaine hydrochloride, methylparaben, propylparaben and water for injections – up to 1 Jr.
Pharmacological properties
The hepatoprotective effect of the drug is due to the properties of the active substances included in its composition. L-ornithine, participating in the Krebs ornithine cycle of urea formation (formation of urea from ammonia), reduces the level of ammonia in the body, which is increased in liver diseases, promotes the synthesis of insulin and somatotropin, activates protein metabolism. L-citrulline is an amino acid that participates in the cycle of urea formation, contributes to the formation and removal of urea from the body. L-arginine (amino-guanide-valeric acid) stimulates cellular metabolism, promotes detoxification and removal of ammonia, regulates blood sugar levels and reduces lactic acidosis caused by muscle strain, activates the system of nitrogen-containing enzymes that synthesize nitrosogroup (NO), providing arterial tone is necessary. Betaine (trimethylglycine) has a choleretic and lipotropic effect, activates metabolic methylation in the liver and synthesis of phospholipids of cell membranes. Functioning as an alternative donor of methyl groups in the conversion of methionine from homocysteine, it can replace defects in methylation reactions caused by a malfunction of the folate cycle and vitamin B12 deficiency. Sorbitol has a detoxifying and choleretic effect, provides replenishment of the volume of circulating blood. The drug is quickly absorbed from the injection site, passes histohematal barriers and is distributed to all organs and tissues. It is partially utilized in metabolic processes, the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect. Functioning as an alternative donor of methyl groups in the conversion of methionine from homocysteine, it can replace defects in methylation reactions caused by a malfunction of the folate cycle and vitamin B12 deficiency. Sorbitol has a detoxifying and choleretic effect, provides replenishment of the volume of circulating blood. The drug is quickly absorbed from the injection site, passes histohematal barriers and is distributed to all organs and tissues. It is partially utilized in metabolic processes, the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect. Functioning as an alternative donor of methyl groups in the conversion of methionine from homocysteine, it can replace defects in methylation reactions caused by a malfunction of the folate cycle and vitamin B12 deficiency. Sorbitol has a detoxifying and choleretic effect, provides replenishment of the volume of circulating blood. The drug is quickly absorbed from the injection site, passes histohematal barriers and is distributed to all organs and tissues. It is partially utilized in metabolic processes, the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect. caused by a malfunction of the folate cycle and a lack of vitamin B12. Sorbitol has a detoxifying and choleretic effect, provides replenishment of the volume of circulating blood. The drug is quickly absorbed from the injection site, passes histohematal barriers and is distributed to all organs and tissues. It is partially utilized in metabolic processes, the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect. caused by a malfunction of the folate cycle and a lack of vitamin B12. Sorbitol has a detoxifying and choleretic effect, provides replenishment of the volume of circulating blood. The drug is quickly absorbed from the injection site, passes histohematal barriers and is distributed to all organs and tissues. It is partially utilized in metabolic processes, the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect. the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect. the rest is excreted by the kidneys. In terms of the degree of impact on the body, Hepagard is classified as a low-hazard substance; in therapeutic doses, it does not have an embryotoxic, teratogenic, carcinogenic, or sensitizing effect.
Application
Hepagard is prescribed to animals independently or as part of complex therapy for acute and chronic liver diseases of various etiologies, in order to normalize the function and regeneration of liver cells after endo- and exotoxicosis, somatic and infectious diseases, as well as to reduce the hepatotoxic effect of drugs.
Dosage
The drug is used only as prescribed by a veterinarian. The dose is calculated depending on the weight of the animal and its age. Hepagard is administered intramuscularly (deeply), intravenously (very slowly) or subcutaneously. The latter method is used more often for small dogs, puppies and kittens, as it is a bit difficult for them to give intramuscular injections. Depending on the severity of the pathological process and the general condition of the animal, the medicine is administered 1 or 2 times per 24 hours for a course of 5-7 days. In severe cases, it is allowed to extend the course of treatment up to 2 weeks. Hepagard is compatible with any medicines and feed additives for animals. For pregnant and lactating females, the drug is prescribed only after assessing all the risks for the offspring, if it is of value.
Standard doses for administration:
Adult dogs – depending on the breed, 2-5 ml.
Puppies of small breeds – only according to the assessment of the veterinarian, with a dosage starting from 0.3 ml.
Puppies of medium species – at the discretion of the veterinarian, with a dosage of 0.5 ml. Puppies of large breeds – with a dosage of 1 ml.
Adult cats – depending on weight from 2 to 5 ml per head.
Kittens – from 0.3 ml. The exact dose is calculated for each specific kitten by the veterinarian.
Horses – from 50 to 100 ml per animal, depending on the disease and body weight. Foals – from 1 ml per 5-10 kg of weight, depending on the severity of the pathology.
Cows – from 50 to 100 ml per animal.
Calves – 1 ml per 5-10 kg of weight, depending on the severity of the pathology.
Pigs – 10-15 ml depending on the weight of the animal.
Piglets – 3-5 ml per individual, depending on the severity of the pathology and weight. Sheep – 10-15 ml according to body weight.
Lambs – from 3 to 5 ml per individual depending on body weight.
Violation of the dosage suggested by the veterinarian and omissions in the introduction of the drug make the therapy much less effective.
*Kilograms to a Pounds conversion table
Kilograms (kg) | Pounds (lb) | Pounds+Ounces (lb+oz) |
0.1 kg | 0.220 lb | 0 lb 3.527 oz |
1 kg | 2.205 lb | 2 lb 3.274 oz |
5 kg | 11.023 lb | 11 lb 0.370 oz |
10 kg | 22.046 lb | 22 lb 0.740 oz |
Contraindication
Contraindication to use is increased individual sensitivity of the animal to the components of the drug (including in the anamnesis).
Side effects
Side effects and complications when using Hepagard according to this instruction, as a rule, are not observed. With increased individual sensitivity of animals to the components of the drug and the appearance of allergic reactions, its use is stopped and, if necessary, the animal is prescribed antihistamines and means of symptomatic therapy.
Reservation
Slaughter of animals for meat is allowed no earlier than 24 hours after the last use of the drug. The meat of animals forcibly slaughtered before the end of the specified period can be used as feed for fur animals. Milk obtained from animals during the treatment period and within 24 hours (2 milkings) after the last administration of the drug is prohibited to be used for food purposes. Such milk after heat treatment can be used as animal feed.
Release form
The drug is released in glass bottles of 100 ml, closed with a rubber stopper with an aluminum cap and placed in boxes.
Storage
In the manufacturer’s closed packaging, in a dry place protected from direct sunlight, in a place inaccessible to children and animals. Separately from food and feed at a temperature of 5 °C to 25 °C.
Shelf life – 2 years from the date of manufacture, after opening the bottle – no more than 21 days.